Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
A nice demonstration again in a placebo controlled trial that recombinant EPO is safe and effective in anemic cancer patients on chemorx. The three times weekly dose is more commonly replaced now with the once weekly dose, starting at 40,000 U SQ. – David H. Henry
Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales.
This helpful article offers increased understanding and ability to utilize the functional assessment of cancer therapy (FACT) scale. – Patricia Ford
Important to attempt review, but too much variability in studies to form meaningful conclusion. – Patricia Ford